# Personalised Immunotherapy Platform

> **NCT06536257** · — · RECRUITING · sponsor: **Melanoma Institute Australia** · enrollment: 1000 (estimated)

## Conditions studied

- Melanoma
- Cutaneous Squamous Cell Carcinoma
- Basal Cell Carcinoma
- Merkel Cell Carcinoma
- Solid Tumor

## Interventions

- **OTHER:** Predictive model

## Key facts

- **NCT ID:** NCT06536257
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-08
- **Primary completion:** 2027-06-01
- **Final completion:** 2037-06-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536257, "Personalised Immunotherapy Platform". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06536257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*